August 14, 2020 Bristol hopes to Tyk the psoriasis box The company’s massive clinical programme with BMS-986165 is set to deliver its first pivotal data later this year.
September 17, 2018 Tyk2 reaches tipping point Bristol-Myers Squibb is ahead in a new oral class that could bring similar efficacy to current injectables for autoimmune diseases – but Pfizer seems less keen.